QGEN Stock Overview
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$46.63|
|52 Week High||US$58.00|
|52 Week Low||US$41.32|
|1 Month Change||2.19%|
|3 Month Change||-2.87%|
|1 Year Change||-3.96%|
|3 Year Change||14.99%|
|5 Year Change||39.07%|
|Change since IPO||2,275.03%|
Recent News & Updates
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|QGEN||US Life Sciences||US Market|
Return vs Industry: QGEN exceeded the US Life Sciences industry which returned -15.9% over the past year.
Return vs Market: QGEN exceeded the US Market which returned -18.5% over the past year.
|QGEN Average Weekly Movement||3.9%|
|Life Sciences Industry Average Movement||11.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: QGEN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: QGEN's weekly volatility (4%) has been stable over the past year.
About the Company
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen Fundamentals Summary
|QGEN fundamental statistics|
Is QGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|QGEN income statement (TTM)|
|Cost of Revenue||US$752.86m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.37|
|Net Profit Margin||23.29%|
How did QGEN perform over the long term?See historical performance and comparison
Is QGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for QGEN?
Other financial metrics that can be useful for relative valuation.
|What is QGEN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does QGEN's PE Ratio compare to its peers?
|QGEN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (38.3x).
Price to Earnings Ratio vs Industry
How does QGEN's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?
Price-To-Earnings vs Industry: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the US Life Sciences industry average (30.5x)
Price to Earnings Ratio vs Fair Ratio
What is QGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||19.7x|
|Fair PE Ratio||21.2x|
Price-To-Earnings vs Fair Ratio: QGEN is good value based on its Price-To-Earnings Ratio (19.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).
Share Price vs Fair Value
What is the Fair Price of QGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: QGEN ($46.63) is trading below our estimate of fair value ($72.98)
Significantly Below Fair Value: QGEN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: QGEN is poor value based on its PEG Ratio (2.8x)
Discover undervalued companies
How is Qiagen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QGEN's forecast earnings growth (7% per year) is above the savings rate (1.9%).
Earnings vs Market: QGEN's earnings (7% per year) are forecast to grow slower than the US market (14% per year).
High Growth Earnings: QGEN's earnings are forecast to grow, but not significantly.
Revenue vs Market: QGEN's revenue (6% per year) is forecast to grow slower than the US market (8.4% per year).
High Growth Revenue: QGEN's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (12.9%).
Discover growth companies
How has Qiagen performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QGEN has high quality earnings.
Growing Profit Margin: QGEN's current net profit margins (23.3%) are higher than last year (21.7%).
Past Earnings Growth Analysis
Earnings Trend: QGEN's earnings have grown significantly by 47% per year over the past 5 years.
Accelerating Growth: QGEN's earnings growth over the past year (20.1%) is below its 5-year average (47% per year).
Earnings vs Industry: QGEN earnings growth over the past year (20.1%) underperformed the Life Sciences industry 21%.
Return on Equity
High ROE: QGEN's Return on Equity (16.6%) is considered low.
Discover strong past performing companies
How is Qiagen's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: QGEN's short term assets ($2.1B) exceed its short term liabilities ($957.3M).
Long Term Liabilities: QGEN's short term assets ($2.1B) exceed its long term liabilities ($2.0B).
Debt to Equity History and Analysis
Debt Level: QGEN's net debt to equity ratio (22.1%) is considered satisfactory.
Reducing Debt: QGEN's debt to equity ratio has increased from 44.2% to 60% over the past 5 years.
Debt Coverage: QGEN's debt is well covered by operating cash flow (36.9%).
Interest Coverage: QGEN's interest payments on its debt are well covered by EBIT (15.8x coverage).
Discover healthy companies
What is Qiagen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as QGEN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thierry Bernard (56 yo)
Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board and had been its Interim Chief Executive Officer since October 2019 un...
CEO Compensation Analysis
Compensation vs Market: Thierry's total compensation ($USD2.02M) is below average for companies of similar size in the US market ($USD13.61M).
Compensation vs Earnings: Thierry's compensation has been consistent with company performance over the past year.
Experienced Management: QGEN's management team is considered experienced (4.4 years average tenure).
Experienced Board: QGEN's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QGEN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Qiagen N.V.'s employee growth, exchange listings and data sources
- Name: Qiagen N.V.
- Ticker: QGEN
- Exchange: NYSE
- Founded: 1986
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$10.606b
- Shares outstanding: 227.45m
- Website: https://www.qiagen.com
Number of Employees
- Qiagen N.V.
- Hulsterweg 82
- 5912 PL
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.